Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Angelman syndrome
Biotech
RA Capital launches Oak Hill Bio onto the Nasdaq via SPAC
Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital's Research Alliance Corporation III to fund a genetic disease candidate.
Will Maddox
Jul 27, 2026 3:25pm
Biogen walks away from Ionis-partnered ALS, Angelman prospects
May 16, 2024 9:24am
Roche drops antisense drug after seeing early efficacy data
Jun 23, 2023 5:00am
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Dec 14, 2022 7:15am
Ultragenyx ready to sign away $75M for Angelman partner GeneTx
Jul 18, 2022 10:16pm
Ultragenyx granted go-ahead to up doses for Angelman therapy
Jan 5, 2022 11:11am
